ライフサイエンスコーパス: gemtuzumab

1 ceive an initial dose of the immunoconjugate gemtuzumab ozogamicin (6 mg/m(2) intravenously).

2 Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoco

3 Induction 2 consisted of ADE with or without gemtuzumab ozogamicin (GO anti-CD33 monoclonal antibody)

4 ated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in

5 ) and arsenic trioxide (ATO) with or without gemtuzumab ozogamicin (GO) but without traditional cytot

6 Gemtuzumab ozogamicin (GO) contains an anti-CD33 antibod

7 Emerging data with gemtuzumab ozogamicin (GO) demonstrate target validity a

8 Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults w

9 We investigated treatment with gemtuzumab ozogamicin (GO) in 51 patients aged 65 years

10 ndomized phase 3 trial evaluating the use of gemtuzumab ozogamicin (GO) in an intensive consolidation

11 ated the efficacy of this regimen with added gemtuzumab ozogamicin (GO) in high-risk patients.

12 The encouraging results of gemtuzumab ozogamicin (GO) in newly diagnosed AML, and p

13 Gemtuzumab ozogamicin (GO) is a novel immunoconjugate th

14 Gemtuzumab ozogamicin (GO) is an immunoconjugate between

15 y Group (SWOG), which tested the addition of gemtuzumab ozogamicin (GO) to a 317 regimen in a randomi

16 val for the majority of patients when adding gemtuzumab ozogamicin (GO) to induction chemotherapy.

17 ted the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and pos

18 In 2000, gemtuzumab ozogamicin (GO) was granted accelerated appro

19 Purpose Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjug

20 Gemtuzumab ozogamicin (GO), a monoclonal antibody used i

21 (AML) leukemic blasts and is the target for gemtuzumab ozogamicin (GO), a toxin-conjugated anti-CD33

22 Gemtuzumab ozogamicin (GO), an immunoconjugate of an ant

23 oid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO).

24 The antibody-targeted therapeutic, gemtuzumab ozogamicin (GO, Mylotarg), is approved for tr

25 n the role of postconsolidation therapy with gemtuzumab ozogamicin (GO; Mylotarg) in children with ac

26 Gemtuzumab ozogamicin (GO; Mylotarg), a novel immunoconj

27 While gemtuzumab ozogamicin (GTMZ) is commonly used in the tre

28 Gemtuzumab ozogamicin (Mylotarg) targets leukemia cells

29 momab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market.

30 oconjugates of calicheamicin, exemplified by gemtuzumab ozogamicin (Mylotarg), is a clinically valida

31 Liver injury developed in 11 patients after gemtuzumab ozogamicin administration; it was manifested

32 t Pgp plays a role in clinical resistance to gemtuzumab ozogamicin and suggest that treatment trials

33 Antibody-directed therapy by means of gemtuzumab ozogamicin as an adjunct to induction chemoth

34 Gemtuzumab ozogamicin can be safely added to conventiona

35 ples from relapsed AML patients eligible for gemtuzumab ozogamicin clinical trials were assayed for P

36 The addition of gemtuzumab ozogamicin did not increase the proportion of

37 wed the course of 23 patients who were given gemtuzumab ozogamicin for AML that had relapsed after he

38 pt has been reinvigorated by the approval of gemtuzumab ozogamicin for treatment of acute myeloid leu

39 May 1, 2013, that included an assessment of gemtuzumab ozogamicin given to adults (aged 15 years and

40 atic sinusoidal liver injury developed after gemtuzumab ozogamicin infusion.

41 ilure or sepsis at a median of 40 days after gemtuzumab ozogamicin infusion.

42 hat was sustained for at least 60 days after gemtuzumab ozogamicin infusion.

43 Emerging clinical data indicate that gemtuzumab ozogamicin is efficacious not only for acute

44 eatment of acute myeloid leukemia (AML) with gemtuzumab ozogamicin may result in liver injury.

45 isease, 19; refractory disease, 10) received gemtuzumab ozogamicin ranging from 6 to 9 mg/m2 per dose

46 However, the contribution of Pgp to gemtuzumab ozogamicin resistance is poorly defined.

47 These data suggest that the use of gemtuzumab ozogamicin should be reassessed and its licen

48 However, the addition of gemtuzumab ozogamicin significantly reduced the risk of

49 tion of sinusoidal collagen, suggesting that gemtuzumab ozogamicin targets CD33(+) cells residing in

50 atient data to assess the efficacy of adding gemtuzumab ozogamicin to induction chemotherapy in adult

51 However, survival benefit from gemtuzumab ozogamicin was not associated with MFC-MRD ch

52 Gemtuzumab ozogamicin was relatively well tolerated at 6

53 geting the CD33 differentiation antigen with gemtuzumab ozogamicin was the first attempt of such an a

54 Gemtuzumab ozogamicin was the first example of antibody-

55 and suggest that treatment trials combining gemtuzumab ozogamicin with MDR reversal agents are warra

56 concomitant azole antifungal prophylaxis and gemtuzumab ozogamicin with the first course of chemother

57 CD33-directed antibody-drug conjugates (gemtuzumab ozogamicin) have been shown to improve overal

58 d by azacitidine, 75 mg/m(2) for 7 days, and gemtuzumab ozogamicin, 3 mg/m(2) on day 8, in older pati

59 ated the safety and efficacy of single-agent gemtuzumab ozogamicin, a humanized anti-CD33 antibody-ta

60 r patients benefit from the incorporation of gemtuzumab ozogamicin, an anti-CD33 mAb toxin, into indu

61 Gemtuzumab ozogamicin, an immunoconjugate of an anti-CD3

62 Mylotarg (gemtuzumab ozogamicin, CMA-676; Wyeth-Ayerst Laboratorie

63 out a single dose of the monoclonal antibody gemtuzumab ozogamicin, followed by autologous stem-cell

64 effective agents, such as purine analogs or gemtuzumab ozogamicin, is still under investigation, whe

65 Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors,

66 e anthracycline, adding other agents such as gemtuzumab ozogamicin, or through 'timed sequential' the

67 In vitro gemtuzumab ozogamicin--induced apoptosis was also evalua

68 s predicted a greater or lesser benefit from gemtuzumab ozogamicin.

69 less than 3.5 months after the last dose of gemtuzumab ozogamicin; 6 (40%) developed VOD.

70 We administered gemtuzumab ozogamycin ("mylotarg"; 9 mg/m(2) day 1 or 5)

71 received chemotherapy, generally 9 mg/m2 of gemtuzumab ozogamycin(GO) on day 1 of induction.